LY364947

LY364947 is a selective inhibitor of the TGFβ/Activin/NODAL pathway that inhibits ALK5. LY364947 less effectively inhibits TGFβRII. In combination with valproic acid, can replace SOX2 in reprogramming of mouse embryonic fibroblasts transduced with OCT4, KLF4 and c-MYC. Blocks chondrogenesis induced by mechanical load in human mesenchymal stem cells. Restores the hematopoietic potential of mouse para-aortic splanchnopleural cells deficient for the Evi-1 transcription factor. Impairs definitive endoderm differentiation competence in human embryonic stem. Blocks TGF-β-induced endothelial-to-mesenchymal transition of NMuMg mammary epithelial cells or mouse ES cell-derived endothelial cells. Suppresses colony-forming ability of mouse and human leukemia-initiating cells cultured with OP-9 stromal cells, and, when combined with imatinib, reduces lethality in a mouse model of chronic myeloid leukemia. Reduces invasiveness of MDA-MB-231 breast cancer cells in a matrigel invasion assay.